Advertisement

Rheumatology International

, Volume 35, Issue 4, pp 709–717 | Cite as

Pathological spectrums and renal prognosis of severe lupus patients with rapidly progressive glomerulonephritis

  • Shasha Chen
  • Hao Chen
  • Zhengzhao Liu
  • Haitao Zhang
  • Weixin Hu
  • Zheng TangEmail author
  • Zhihong Liu
Original Article - Observational Research

Abstract

The objectives of the study were to investigate the pathological features and renal prognosis of severe lupus patients with rapidly progressive glomerulonephritis. One hundred and one cases of biopsy-proven severe LN with rapidly progressive glomerulonephritis (RPGN) were analyzed in this retrospective study. Another 200 severe LN patients without RPGN were randomly enrolled as a control group. Their clinicopathological data and long-term outcome were compared. There were 76 females and 25 males with an average age of 31.9 ± 14.2 years followed for a median period of 4 years. Compared with controls, patients with RPGN had shorter LN duration (p = 0.008), higher level of creatinine (p < 0.001), severe anemia (p = 0.037), heavier hematuria (p < 0.001), severe tubular injury parameters [NAG (p < 0.001), RBP (p < 0.001), C3 (p < 0.001)], higher scores of AI (p = 0.001) and CI (p = 0.004), higher proportions of glomerular sclerosis (0.033) and crescents (p < 0.001), severe tubulointerstitial lesions (p < 0.001) and interstitial inflammation (p < 0.001), lower rate of complete remission (33.9 vs 68.2 %) and higher rate of treatment failure (46.8 vs 7.9 %). The 3-, 5- and 10-year cumulative renal survival rates of RPGN and non-RPGN patients were 65.1 versus 53.9 versus 42.9 and 96.9 versus 94.9 versus 91.7 %, respectively. Multivariate analysis revealed that SCr concentration and the proportion of crescents were the most important risk factors for end-stage renal disease (ESRD) in severe LN with RPGN (p < 0.001). In conclusion, RPGN occurred in 3.6 % of LN and is associated with severe renal manifestations, serious sclerotic and crescentic glomeruli lesions, severe tubulointerstitial inflammation, atrophy and fibrosis, prominent leukocyte infiltration and worse treatment response. Multivariate analysis revealed that SCr concentration and the proportion of crescents were the most important risk factors for ESRD. 57.1 % of severe LN patients with RPGN might progress to ESRD within 10 years.

Keywords

Crescent Lupus nephritis Rapidly progressive glomerulonephritis (RPGN) Renal survival Risk factors 

Notes

Conflict of interest

We declare that we have no conflict of interest.

Supplementary material

296_2014_3140_MOESM1_ESM.doc (270 kb)
Supplementary material 1 (DOC 270 kb)

References

  1. 1.
    Sumethkul V, Chalermsanyakorn P, Changsirikulchai S, Radinahamed P (2000) Lupus nephritis: a challenging cause of rapidly progressive crescentic glomerulonephritis. Lupus 9:424–428CrossRefPubMedGoogle Scholar
  2. 2.
    Masani NN, Imbriano LJ, D’Agati VD, Markowitz GS (2005) Sle and rapidly progressive glomerulonephritis. Am J Kidney Dis 45:950–955CrossRefPubMedGoogle Scholar
  3. 3.
    Jennette JC (2003) Rapidly progressive crescentic glomerulonephritis. Kidney Int 63:1164–1177CrossRefPubMedGoogle Scholar
  4. 4.
    Glassock R (1978) A clinical and immunopathologic dissection of rapidly progressive glomerulonephritis. Nephron 22:253–264CrossRefPubMedGoogle Scholar
  5. 5.
    Yeung C, Wong K, Wong W, Ng M, Chan K, Ng W (1984) Crescentic lupus glomerulonephritis. Clin Nephrol 21:251–258PubMedGoogle Scholar
  6. 6.
    Andrassy K, Küster S, Waldherr R, Ritz E (1991) Rapidly progressive glomerulonephritis: analysis of prevalence and clinical course. Nephron 59:206–212CrossRefPubMedGoogle Scholar
  7. 7.
    Niaudet P (2000) Treatment of lupus nephritis in children. Pediatr Nephrol 14:158–166CrossRefPubMedGoogle Scholar
  8. 8.
    Bogdanović R, Nikolić V, Pašić S, Dimitrijević J, Lipkovska-Marković J, Erić-Marinković J, Ognjanović M, Minić A, Stajić N (2004) Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol 19:36–44CrossRefPubMedGoogle Scholar
  9. 9.
    Weening JJ, D D’AGATI V, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65:521–530CrossRefPubMedGoogle Scholar
  10. 10.
    Mosca M, Pasquariello A, Tavoni A, Moriconi L, Moneta I, Innocenti M, Bencivelli W, Bombardieri S (1997) Predictors of renal outcome in diffuse proliferative glomerulonephritis in systemic lupus erythematosus. Lupus 6:371–378CrossRefPubMedGoogle Scholar
  11. 11.
    Sumboonnanonda A, Vongjirad A, Suntornpoch V, Laohapand T, Parichatikanond P (1998) Renal pathology and long-term outcome in childhood sle. J Med Assoc Thail 81:830–834Google Scholar
  12. 12.
    Huong D, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, Godeau P, Piette J (1999) Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine 78:148–166CrossRefPubMedGoogle Scholar
  13. 13.
    Wang L-C, Yang Y-H, Lu M-Y, Chiang B-L (2003) Retrospective analysis of mortality and morbidity of pediatric systemic lupus erythematosus in the past two decades. J Microbiol Immunol Infect 36:203–208PubMedGoogle Scholar
  14. 14.
    Hochberg MC (1997) Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMedGoogle Scholar
  15. 15.
    Lewis EJ, Hunsicker LG, Lan S-P, Rohde RD, Lachin JM (1992) A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 326:1373–1379CrossRefPubMedGoogle Scholar
  16. 16.
    Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ (2008) Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 3:46–53CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Katz SM (1982) Renal disease: classification and atlas of glomerular diseases. JAMA 248(16):2053–2054CrossRefGoogle Scholar
  18. 18.
    Austin H, Muenz LR, Joyce KM, Antonovych TT, Balow JE (1984) Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 25:689–695CrossRefPubMedGoogle Scholar
  19. 19.
    Solez K, Axelsen R, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Croke BP, Droz D, Dunnill MS, Halloran PF (1993) International standardization of criteria for the histologic diagnosis of renal allograft rejection: the banff working classification of kidney transplant pathology. Kidney Int 44:411CrossRefPubMedGoogle Scholar
  20. 20.
    Hsieh C, Chang A, Brandt D, Guttikonda R, Utset TO, Clark MR (2011) Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res 63:865–874CrossRefGoogle Scholar
  21. 21.
    Banfi G, Bertani T, Boeri V, Faraggiana T, Mazzucco G, Monga G, Sacchi G (1991) Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Am J Kidney Dis 18:240–248CrossRefPubMedGoogle Scholar
  22. 22.
    Appel G, Pirani C, D’Agati V (1994) Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 4:1499–1515PubMedGoogle Scholar
  23. 23.
    Descombes E, Droz D, Drouet L, Grünfeld J-P, Lesavre P (1997) Renal vascular lesions in lupus nephritis. Medicine 76:355–368CrossRefPubMedGoogle Scholar
  24. 24.
    Schwartz M (1992) Lupus vasculitis. Contrib Nephrol 99:35PubMedGoogle Scholar
  25. 25.
    Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Int Med 135:248–257CrossRefPubMedGoogle Scholar
  26. 26.
    Chan T, Tse K, Tang CS, Lai K, Li F (2005) Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 14:265–272CrossRefPubMedGoogle Scholar
  27. 27.
    Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD (2000) Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 35:904–914CrossRefPubMedGoogle Scholar
  28. 28.
    Mok CC, Ho CTK, Chan KW, Lau CS, Wong RWS (2002) Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 46:1003–1013CrossRefPubMedGoogle Scholar
  29. 29.
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A, Bell A, Bloch DA, Corey PN, Decker JL (1992) Derivation of the sledai. A disease activity index for lupus patients. Arthritis Rheum 35:630–640CrossRefPubMedGoogle Scholar
  30. 30.
    Moeller MJ, Smeets B (2013) Novel target in the treatment of rpgn: the activated parietal cell. Nephrol Dial Transpl 28:489–492CrossRefGoogle Scholar
  31. 31.
    Keller F, Oehlenberg B, Kunzendorf U, Schwarz A, Offermann G (1989) Long-term treatment and prognosis of rapidly progressive glomerulonephritis. Clin Nephrol 31:190–197PubMedGoogle Scholar
  32. 32.
    Rees A, Cameron J (1998) Crescentic glomerulonephritis. In: Cameron JS, Davison AM, Grunfeld JP, Kerr D, Ritz E (eds) Oxford textbook of clinical nephrology, vol 1992. Oxford University Press, New York, pp 418–438Google Scholar
  33. 33.
    Ponticelli C, Imbasciati E, Brancaccio D, Tarantino A, Rivolta E (1974) Acute renal failure in systemic lupus erythematosus. Br Med J 3:716CrossRefPubMedCentralPubMedGoogle Scholar
  34. 34.
    Zhu D, Qu Z, Tan Y, Yu F, Zhao MH (2011) Acute kidney injury in chinese patients with lupus nephritis: a large cohort study from a single center. Lupus 20:1557–1565CrossRefPubMedGoogle Scholar
  35. 35.
    Yu F, Tan Y, Liu G, Wang S-x, Zou W-z, Zhao M-h (2009) Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int 76:307–317CrossRefPubMedGoogle Scholar
  36. 36.
    Schwartz MM, Roberts JL, Lewis EJ (1983) Necrotizing glomerulitis of systemic lupus erythematosus. Hum Pathol 14:158–167CrossRefPubMedGoogle Scholar
  37. 37.
    Ferrario F, Napodano P, Giordano A, Gandini E, Boeri R, D’Amico G (1992) Peculiar type of focal and segmental lupus glomerulitis: glomerulonephritis or vasculitis? Contrib Nephrol 99:86PubMedGoogle Scholar
  38. 38.
    Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J (2001) Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 59:2156–2163CrossRefPubMedGoogle Scholar
  39. 39.
    Hill GS, Delahousse M, Nochy D, Bariety J (2005) Class iv-s versus class iv-g lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int 68:2288–2297CrossRefPubMedGoogle Scholar
  40. 40.
    Mittal B, Hurwitz S, Rennke H, Singh AK (2004) New subcategories of class iv lupus nephritis: are there clinical, histologic, and outcome differences? Am J Kidney Dis 44:1050–1059CrossRefPubMedGoogle Scholar
  41. 41.
    Schwartz MM, Korbet SM, Lewis EJ (2008) The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transpl 23:1298–1306CrossRefGoogle Scholar
  42. 42.
    Schwartz M, Korbet S, Katz R, Lewis E (2009) Evidence of concurrent immunopathological mechanisms determining the pathology of severe lupus nephritis. Lupus 18:149–158CrossRefPubMedGoogle Scholar
  43. 43.
    Behara VY, Whittier WL, Korbet SM, Schwartz MM, Martens M, Lewis EJ (2010) Pathogenetic features of severe segmental lupus nephritis. Nephrol Dial Transpl 25:153–159CrossRefGoogle Scholar
  44. 44.
    Chen S, Tang Z, Zhang Y, Liu Z, Zhang H, Hu W (2013) Significance of histological crescent formation in patients with diffuse proliferative lupus nephritis. Am J Nephrol 38:445–452CrossRefPubMedGoogle Scholar
  45. 45.
    Küster S, Apenberg S, Andrassy K, Ritz E (1992) Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Contrib Nephrol 99:94PubMedGoogle Scholar
  46. 46.
    Sen D, Isenberg DA (2003) Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus 12:651–658CrossRefPubMedGoogle Scholar
  47. 47.
    Nasr SH, D’Agati VD, Park H-R, Sterman PL, Goyzueta JD, Dressler RM, Hazlett SM, Pursell RN, Caputo C, Markowitz GS (2008) Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin J Am Soc Nephrol 3:682–690CrossRefPubMedCentralPubMedGoogle Scholar
  48. 48.
    Jennette JC, Xiao H, Falk RJ (2006) Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 17:1235–1242CrossRefPubMedGoogle Scholar
  49. 49.
    Couser WG (1988) Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 11:449–464CrossRefPubMedGoogle Scholar
  50. 50.
    Li X, Chen N (2013) Management of crescentic glomerulonephritis: what are the recent advances. Contrib Nephrol 181:229–239CrossRefPubMedGoogle Scholar
  51. 51.
    Tang Z, Yang G, Yu C, Yu Y, Wang J, Hu W, Zeng C, Chen H, Liu Z, Li L (2008) Effects of mycophenolate mofetil for patients with crescentic lupus nephritis. Nephrology 13:702–707CrossRefPubMedGoogle Scholar
  52. 52.
    Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R, D’Cruz DP (2013) Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 22:574–582CrossRefPubMedGoogle Scholar
  53. 53.
    Sinha A, Puri K, Hari P, Dinda AK, Bagga A (2013) Etiology and outcome of crescentic glomerulonephritis. Indian Pediatr 50:283–288CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Shasha Chen
    • 1
  • Hao Chen
    • 1
  • Zhengzhao Liu
    • 1
  • Haitao Zhang
    • 1
  • Weixin Hu
    • 1
  • Zheng Tang
    • 1
    Email author
  • Zhihong Liu
    • 1
  1. 1.National Clinical Research Centre of Kidney Desease, Jinling HospitalNanjing University School of MedicineNanjingChina

Personalised recommendations